Eduardo Arboli-Rodriguez

Sevilla, AN, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications

Co-mutation signatures are age-dependent and impact the prognosis in NPM1-mutated acute myeloid leukemia: a PETHEMA multicenter study.

Co-mutation signatures are age-dependent and impact the prognosis in NPM1-mutated acute myeloid leukemia: a PETHEMA multicenter study.

Journal: Haematologica
Published: July 07, 2026

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

Journal: American journal of hematology
Published: June 23, 2026

Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

Journal: American journal of hematology
Published: April 24, 2026

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Journal: Haematologica
Published: March 10, 2026

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.

Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study.

Journal: Blood
Published: February 05, 2026

Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study.

Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study.

Journal: American journal of hematology
Published: February 05, 2026

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025

DNA Damage Sensing and TP53 Function as Modulators of Sensitivity to Calicheamicin-Based Antibody-Drug Conjugates for Acute Leukemia.

DNA Damage Sensing and TP53 Function as Modulators of Sensitivity to Calicheamicin-Based Antibody-Drug Conjugates for Acute Leukemia.

Journal: Cancers
Published: November 26, 2025

Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.

Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.

Journal: Cancer
Published: November 03, 2025

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.

Journal: American journal of hematology
Published: October 17, 2025

Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study.

Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study.

Journal: Blood neoplasia
Published: October 15, 2025

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2025
Showing 1-12 of 57

Last Updated: 09/26/2026